Answers are grounded in this paper and cite their sources.
Randomized trial evaluates inflammation targeting using nano-micellar formulation of celecoxib, suggesting reduced side effects.
Objective: Celecoxib (CLX), brand named Celebrex, which belongs to non-steroidal anti-inflammatory drugs family, selectively inhibits the cytokine related cyclooxygenase-2 isoenzyme and thus, possesses less gastrointestinal side effects, have shown to cause stroke, myocard infarction and even death in some cases. In this study we aimed to target inflammation site using CLX uploaded nano-micelles (nano-CLX) made of poly (lactic-co-glycolic) acid (PLGA) to protect other tissues from its side effects.
No takes yet. Share an insight, caveat, or question.
Bahadorı et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: